OA13169A - Azaindole-derivatives as factor Xa inhibitors. - Google Patents

Azaindole-derivatives as factor Xa inhibitors. Download PDF

Info

Publication number
OA13169A
OA13169A OA1200500323A OA1200500323A OA13169A OA 13169 A OA13169 A OA 13169A OA 1200500323 A OA1200500323 A OA 1200500323A OA 1200500323 A OA1200500323 A OA 1200500323A OA 13169 A OA13169 A OA 13169A
Authority
OA
OAPI
Prior art keywords
alkyl
alkylene
unsubstituted
another
mono
Prior art date
Application number
OA1200500323A
Other languages
English (en)
Inventor
Marc Nazare
Volkmar Wehner
David William Will
Kurt Ritter
Matthias Urmann
Hans Matter
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of OA13169A publication Critical patent/OA13169A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
OA1200500323A 2003-05-19 2004-05-05 Azaindole-derivatives as factor Xa inhibitors. OA13169A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03011304A EP1479680A1 (en) 2003-05-19 2003-05-19 Azaindole derivatives as Factor Xa inhibitors

Publications (1)

Publication Number Publication Date
OA13169A true OA13169A (en) 2006-12-13

Family

ID=33040951

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200500323A OA13169A (en) 2003-05-19 2004-05-05 Azaindole-derivatives as factor Xa inhibitors.

Country Status (24)

Country Link
EP (2) EP1479680A1 (es)
JP (1) JP4733642B2 (es)
KR (1) KR20060012636A (es)
CN (1) CN100347172C (es)
AR (1) AR045682A1 (es)
AU (1) AU2004238500B2 (es)
BR (1) BRPI0410429A (es)
CA (1) CA2526084A1 (es)
CL (1) CL2004001079A1 (es)
CR (1) CR8088A (es)
EC (1) ECSP056179A (es)
MA (1) MA27799A1 (es)
MX (1) MXPA05012156A (es)
NO (1) NO20055911L (es)
NZ (1) NZ543669A (es)
OA (1) OA13169A (es)
PE (1) PE20050554A1 (es)
RS (1) RS20050857A (es)
RU (1) RU2330853C2 (es)
TN (1) TNSN05296A1 (es)
TW (1) TW200510411A (es)
UA (1) UA86767C2 (es)
WO (1) WO2004101563A1 (es)
ZA (1) ZA200508150B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2351940T3 (es) * 2005-11-18 2011-02-14 F. Hoffmann-La Roche Ag Derivados de azaindol-2-carboxamida.
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
KR20150044895A (ko) 2012-08-17 2015-04-27 바이엘 크롭사이언스 아게 살곤충제 및 살응애제로서의 아자인돌 카르복실산 아미드 및 아자인돌 티오카르복실산 아미드
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
CN111834531B (zh) * 2019-04-15 2022-04-19 天津大学 一种有机半导体材料、制备方法及应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1241472B (it) 1990-07-06 1994-01-17 Olivier Linda Dispositivo elettromeccanico per la cattura continua in particolare di topi e ratti.
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
AU707653B2 (en) 1994-04-26 1999-07-15 Selectide Corporation Factor Xa inhibitors
ZA964008B (en) * 1995-06-02 1997-07-11 Akzo Nobel Nv Imidazo[1,5a]pyridine derived serine protease inhibitors
EP1040108B1 (en) * 1997-12-19 2004-02-25 Schering Aktiengesellschaft Ortho-anthranilamide derivatives as anti-coagulants
PT1042287E (pt) * 1997-12-24 2005-08-31 Aventis Pharma Gmbh Derivados de indole como inibidores do factor xa
EP0987274A1 (en) 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
JP4241970B2 (ja) * 1998-10-30 2009-03-18 中外製薬株式会社 アミド結合を有するインドール誘導体、及びモノ又はジアザインドール誘導体
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
ES2316383T3 (es) * 1999-09-17 2009-04-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
JP2001294572A (ja) * 2000-02-09 2001-10-23 Dai Ichi Seiyaku Co Ltd 新規スルホニル誘導体
US6436965B1 (en) * 2000-03-02 2002-08-20 Merck Frosst Canada & Co. PDE IV inhibiting amides, compositions and methods of treatment
AU2001273040A1 (en) * 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
CA2440803A1 (en) * 2001-03-07 2002-09-12 Pfizer Products Inc. Modulators of chemokine receptor activity
WO2002080853A2 (en) * 2001-04-09 2002-10-17 Bristol-Myers Squibb Company Fused heterocyclic inhibitors of factor xa
EP1314733A1 (en) * 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
AU2002366801B8 (en) * 2001-12-20 2009-05-21 Osi Pharmaceuticals, Inc. Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use
DE10214832A1 (de) * 2002-04-04 2003-10-16 Merck Patent Gmbh Phenylderivate 4
JP2004203791A (ja) * 2002-12-25 2004-07-22 Dai Ichi Seiyaku Co Ltd 芳香族化合物
JP2004210716A (ja) * 2002-12-27 2004-07-29 Dai Ichi Seiyaku Co Ltd ジアミド誘導体
US7135469B2 (en) * 2003-03-18 2006-11-14 Bristol Myers Squibb, Co. Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors

Also Published As

Publication number Publication date
KR20060012636A (ko) 2006-02-08
TW200510411A (en) 2005-03-16
RU2005139557A (ru) 2007-06-27
MA27799A1 (fr) 2006-03-01
JP4733642B2 (ja) 2011-07-27
WO2004101563A1 (en) 2004-11-25
PE20050554A1 (es) 2005-08-04
UA86767C2 (ru) 2009-05-25
AU2004238500B2 (en) 2010-07-22
AR045682A1 (es) 2005-11-09
EP1479680A1 (en) 2004-11-24
JP2006528214A (ja) 2006-12-14
CN100347172C (zh) 2007-11-07
ECSP056179A (es) 2006-08-30
EP1636226A1 (en) 2006-03-22
MXPA05012156A (es) 2006-08-18
AU2004238500A1 (en) 2004-11-25
NZ543669A (en) 2008-12-24
NO20055911L (no) 2006-02-10
CL2004001079A1 (es) 2005-04-08
ZA200508150B (en) 2007-02-28
CN1791601A (zh) 2006-06-21
HK1089175A1 (zh) 2006-11-24
TNSN05296A1 (en) 2007-07-10
CR8088A (es) 2006-09-22
BRPI0410429A (pt) 2006-06-06
CA2526084A1 (en) 2004-11-25
RU2330853C2 (ru) 2008-08-10
EP1636226B1 (en) 2014-10-15
RS20050857A (sr) 2007-11-15

Similar Documents

Publication Publication Date Title
US20080280946A1 (en) Azaindole-Derivatives As Factor Xa Inhibitors
US7196103B2 (en) Indole derivatives as factor Xa inhibitors
US7223780B2 (en) Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
EP1725550A2 (en) Pyrrole-derivatives as factor xa inhibitors
EP1479675A1 (en) Indazole-derivatives as factor Xa inhibitors
AU2004238498B2 (en) Triazole-derivatives as factor Xa inhibitors
US7741341B2 (en) Benzimidazole-derivatives as factor Xa inhibitors
OA13169A (en) Azaindole-derivatives as factor Xa inhibitors.
EP1636216B1 (en) BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
CA2507624A1 (en) Imidazole-derivatives as factor xa inhibitors
EP1479674A1 (en) Imidiazole-derivatives as factor xa inhibitors